Pten dose dictates cancer progression in the prostate

Lloyd C. Trotman, Masaru Niki, Zohar A. Dotan, Jason A. Koutcher, Antonio Di Cristofano, Andrew Xiao, Alan S. Khoo, Pradip Roy-Burman, Norman M. Greenberg, Terry Van Dyke, Carlos Cordon-Cardo, Pier Paolo Pandolfi

Research output: Contribution to journalArticle

493 Citations (Scopus)

Abstract

Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: Ptenhy/+ > Pten+/- > Pten hy/- (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten pc) mutants. In addition, we have generated and comparatively analyzed two distinct Ptenpc mutants in which Pten is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects key downstream targets such as Akt, p27Kip1, mTOR, and FOXO3. Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.

Original languageEnglish (US)
JournalPLoS Biology
Volume1
Issue number3
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Tumors
Prostate
inactivation
neoplasms
Prostatic Neoplasms
dosage
mutants
Neoplasms
Genes
Homologous Recombination
Tumor Suppressor Genes
knockout mutants
tumor suppressor genes
homologous recombination
prostatic neoplasms
Epithelium
Alleles
epithelium
Incidence
alleles

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., ... Pandolfi, P. P. (2003). Pten dose dictates cancer progression in the prostate. PLoS Biology, 1(3). https://doi.org/10.1371/journal.pbio.0000059

Pten dose dictates cancer progression in the prostate. / Trotman, Lloyd C.; Niki, Masaru; Dotan, Zohar A.; Koutcher, Jason A.; Di Cristofano, Antonio; Xiao, Andrew; Khoo, Alan S.; Roy-Burman, Pradip; Greenberg, Norman M.; Van Dyke, Terry; Cordon-Cardo, Carlos; Pandolfi, Pier Paolo.

In: PLoS Biology, Vol. 1, No. 3, 2003.

Research output: Contribution to journalArticle

Trotman, LC, Niki, M, Dotan, ZA, Koutcher, JA, Di Cristofano, A, Xiao, A, Khoo, AS, Roy-Burman, P, Greenberg, NM, Van Dyke, T, Cordon-Cardo, C & Pandolfi, PP 2003, 'Pten dose dictates cancer progression in the prostate', PLoS Biology, vol. 1, no. 3. https://doi.org/10.1371/journal.pbio.0000059
Trotman, Lloyd C. ; Niki, Masaru ; Dotan, Zohar A. ; Koutcher, Jason A. ; Di Cristofano, Antonio ; Xiao, Andrew ; Khoo, Alan S. ; Roy-Burman, Pradip ; Greenberg, Norman M. ; Van Dyke, Terry ; Cordon-Cardo, Carlos ; Pandolfi, Pier Paolo. / Pten dose dictates cancer progression in the prostate. In: PLoS Biology. 2003 ; Vol. 1, No. 3.
@article{f69af6fceb2c4a2c94ceb1dde2196971,
title = "Pten dose dictates cancer progression in the prostate",
abstract = "Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: Ptenhy/+ > Pten+/- > Pten hy/- (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten pc) mutants. In addition, we have generated and comparatively analyzed two distinct Ptenpc mutants in which Pten is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects key downstream targets such as Akt, p27Kip1, mTOR, and FOXO3. Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.",
author = "Trotman, {Lloyd C.} and Masaru Niki and Dotan, {Zohar A.} and Koutcher, {Jason A.} and {Di Cristofano}, Antonio and Andrew Xiao and Khoo, {Alan S.} and Pradip Roy-Burman and Greenberg, {Norman M.} and {Van Dyke}, Terry and Carlos Cordon-Cardo and Pandolfi, {Pier Paolo}",
year = "2003",
doi = "10.1371/journal.pbio.0000059",
language = "English (US)",
volume = "1",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Pten dose dictates cancer progression in the prostate

AU - Trotman, Lloyd C.

AU - Niki, Masaru

AU - Dotan, Zohar A.

AU - Koutcher, Jason A.

AU - Di Cristofano, Antonio

AU - Xiao, Andrew

AU - Khoo, Alan S.

AU - Roy-Burman, Pradip

AU - Greenberg, Norman M.

AU - Van Dyke, Terry

AU - Cordon-Cardo, Carlos

AU - Pandolfi, Pier Paolo

PY - 2003

Y1 - 2003

N2 - Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: Ptenhy/+ > Pten+/- > Pten hy/- (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten pc) mutants. In addition, we have generated and comparatively analyzed two distinct Ptenpc mutants in which Pten is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects key downstream targets such as Akt, p27Kip1, mTOR, and FOXO3. Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.

AB - Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: Ptenhy/+ > Pten+/- > Pten hy/- (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten pc) mutants. In addition, we have generated and comparatively analyzed two distinct Ptenpc mutants in which Pten is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects key downstream targets such as Akt, p27Kip1, mTOR, and FOXO3. Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=4243110417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243110417&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.0000059

DO - 10.1371/journal.pbio.0000059

M3 - Article

VL - 1

JO - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 3

ER -